Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Thaker

Showing results (81-90 of 256) with videos related to

Pageof 26
Sort By:
Current Medical Research and Opinion|August 17, 2022
Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United StatesJinan Liu, Bruno Emond, Eric M Maiese, et al.
Cancer|October 15, 2010
The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapyNora T Kizer, Premal H Thaker, Feng Gao, et al.
Gynecologic Oncology|April 19, 2015
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group studyRobert L Coleman, Michael W Sill, Premal H Thaker, et al.
Gynecologic Oncology|October 28, 2011
Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancerSaketh R Guntupalli, Israel Zighelboim, Nora T Kizer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 4, 2014
Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinomaIvy Wilkinson-Ryan, Antonina I Frolova, Jingxia Liu, et al.
Brachytherapy|July 9, 2021
Impact of the Radiation Oncology Alternative Payment Model on Brachytherapy ReimbursementNikhil G Thaker, Rehman Meghani, Cassandra Wilson, et al.
Annals of Surgical Oncology|January 25, 2013
Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcomaSaketh R Guntupalli, Dengfeng Cao, Rupal Shroff, et al.
Obstetrics and Gynecology|December 25, 2012
The utility and management of vaginal cytology after treatment for endometrial cancerAkiva P Novetsky, Lindsay M Kuroki, L Stewart Massad, et al.
Gynecologic Oncology Reports|October 2, 2025
Treatment preferences of patients with recurrent or metastatic cervical cancer: a discrete choice experiment in the USPremal H Thaker, Hui Lu, Yitong J Zhang, et al.
Gynecologic Oncology|August 4, 2019
Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up studyTommy R Buchanan, Abigail S Zamorano, Leslie S Massad, et al.
Pageof 26

Showing results (81-90 of 256) with videos related to

Sort By:
Pageof 26
Current Medical Research and Opinion|August 17, 2022
Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United StatesJinan Liu, Bruno Emond, Eric M Maiese, et al.
Cancer|October 15, 2010
The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapyNora T Kizer, Premal H Thaker, Feng Gao, et al.
Gynecologic Oncology|April 19, 2015
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group studyRobert L Coleman, Michael W Sill, Premal H Thaker, et al.
Gynecologic Oncology|October 28, 2011
Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancerSaketh R Guntupalli, Israel Zighelboim, Nora T Kizer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 4, 2014
Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinomaIvy Wilkinson-Ryan, Antonina I Frolova, Jingxia Liu, et al.
Brachytherapy|July 9, 2021
Impact of the Radiation Oncology Alternative Payment Model on Brachytherapy ReimbursementNikhil G Thaker, Rehman Meghani, Cassandra Wilson, et al.
Annals of Surgical Oncology|January 25, 2013
Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcomaSaketh R Guntupalli, Dengfeng Cao, Rupal Shroff, et al.
Obstetrics and Gynecology|December 25, 2012
The utility and management of vaginal cytology after treatment for endometrial cancerAkiva P Novetsky, Lindsay M Kuroki, L Stewart Massad, et al.
Gynecologic Oncology Reports|October 2, 2025
Treatment preferences of patients with recurrent or metastatic cervical cancer: a discrete choice experiment in the USPremal H Thaker, Hui Lu, Yitong J Zhang, et al.
Gynecologic Oncology|August 4, 2019
Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up studyTommy R Buchanan, Abigail S Zamorano, Leslie S Massad, et al.
Pageof 26